Chemical profiling and in-silico prediction of bioactive compounds from Wrightia tinctoria R.Br to treat psoriatic arthritis

Abstract

Psoriatic arthritis (PsA) is an autoimmune-mediated inflammatory skin condition with limited remedies. This study mainly focuses on exploring the therapeutic efficiencies of Wrightia tinctoria R.Br (WT) for the treatment of PsA. Quantification and chemical profiling for the WT leaves were tested using standard in vitro biochemical assays. The ethanol extract of WT has been found to have high amounts of phenolic (24.48±0.03 mg/mL) and flavonoid (29.2±0.16 mg/mL) contents when compared to other solvent fractions. We also conducted a series of in vitro assays, including DPPH, nitric oxide radical scavenging, and protein denaturation inhibition assays, to assess the overall antioxidant and anti-inflammatory capabilities of WT extracts. The GC-MS analysis of WT leaf extract displayed Lup-20(29)-en-3-yl acetate, 24-Norursa-3,12-diene, and 3-O-Methyl-D-fructose as major bioactive compounds. The screened bioactive compounds, via pharmacokinetic and pharmacodynamic analysis, were subjected to density functional theory for energy minimization. Further, the hub targets of PsA were filtered from the Open Target online database to study the drug-target interaction. CD4, CXCL12, KLRD1, MMP9, and SERPINA1 were found to be the primary targets, which have a central role in the disease pathway. Selected disease targets were then docked with the energy-minimized bioactive compounds from WT leaves using PyRx. The results suggest that the ethanolic leaf extract from WT leaves could alter the progression of pathway mediators and effectively manage the PsA.